Skip to main content
Clinical Trials/ACTRN12620000557932
ACTRN12620000557932
Completed
未知

Therapies to prevent progression of COVID-19, including Hydroxychloroquine, Azithromycin, Zinc, Vitamin D with or without Vitamin C, a multi-centre, international, randomized trial: The International ALLIANCE Study - Stage 1

AProf Dr Karin Ried0 sites446 target enrollmentMay 11, 2020

Overview

Phase
未知
Intervention
Not specified
Conditions
COVID-19
Sponsor
AProf Dr Karin Ried
Enrollment
446
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
May 11, 2020
End Date
March 2, 2023
Last Updated
3 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
AProf Dr Karin Ried

Eligibility Criteria

Inclusion Criteria

  • Diagnosis of active COVID\-19
  • Provision of informed consent in writing, can be electronic

Exclusion Criteria

  • 1\) Known G6PD deficiency
  • 2\) Contra\-indication to hydroxychloroquine, azithromycin or Vitamin C: allergy to study interventions, epilepsy, serious hearing or visual problems, history of severe depression, calcium oxalate stones, advanced liver disease, pregnancy or lactating
  • 3\) Already receiving chloroquine, azithromycin, more than 3 grams Vitamin C daily or an experimental antiviral
  • 4\) History of fever (e.g. night sweats, chills) and/or acute respiratory infection (e.g. cough, shortness of breath, sore throat) of more than 7 days’ duration. Note, if study numbers not quickly reached, the investigators may decide to include those with symptoms of longer than 7 days
  • 5\) Calculated creatinine clearance of less than 30 mL/minute
  • 6\) Baseline ECG showing: QTc greater than or equal to (\>\=) 470 for males, QTc greater than or equal to (\>\=) 480 for females
  • 7\) Receipt of a drug known to increase QTc: quetiapine, amiodarone, sotalol

Outcomes

Primary Outcomes

Not specified

Similar Trials